Intercellular adhesion molecule 1 (ICAM-1) is a marker of inflammation and tissue damage. Levels of soluble ICAM-1 (sICAM-1) were measured in 71 patients with chronic C hepatitis treated with interferon (IFN)-a-2a, at baseline and at every 3 months of therapy, and in 42 normal control subjects. The levels of sICAM-1 were significantly higher in the patient than in the control subject group, particularly among cirrhotics. Baseline sICAM-1 levels were similar in responders and nonresponders. By contrast, the concentration of sICAM-1 decreased significantly only in responders during the first 3 months of therapy. The probability of response to treatment, analyzed by Kaplan-Meier analysis, was much higher in the group showing a decrease of sICAM-1 than in the patients who did not show such a decrease. In conclusion, a "longitudinal" evaluation of serum levels of sICAM-1 in the first period of treatment is particularly useful in the identification of patients with high significant probability of response to treatment.
Intercellular adhesion molecule 1 (ICAM-1) is a member of the immunoglobulin supergene family that promotes intercellular adhesion. It is a cell surface glycoprotein and an important early marker of response to inflammatory mediators and immune activation [1, 2] .
ICAM-1 is the ligand for the lymphocyte function-associated antigen-1 (LFA-1) [3, 4] . It attracts lymphocytes expressing LFA-1 and strengthens the binding of lymphocytes to target cells, thus enhancing the efficiency of their interaction [5] . Moreover, ICAM-1 mediates granulocyte extravasation, lymphocyte-mediated cytotoxicity, and cell-cell interactions in immunologic responses [6] .
ICAM-1 has a restricted tissue distribution [2, 7] , but its expression can be up-regulated in response to proinflammatory cytokines, such as interleukin (IL)-1, tumor necrosis factor (TNF)-a, or interferon (IFN)-g, on various cells, including lymphocytes, endothelial cells, keratinocytes, myelocytes, fibro-blasts, tumor cells, biliary epithelial cells, and hepatocytes [7] [8] [9] [10] .
In recent years, attention has been focused on the role of ICAM-1 expression in a variety of inflammatory, autoimmune, and malignant diseases. In particular, immunohistochemical studies have demonstrated that increased tissue expression of ICAM-1 occurs in inflamed tissues, including liver tissue from patients with hepatitis [7, 11] . Hepatocytes in healthy subjects are constantly negative for ICAM-1 staining, which is restricted to the endothelium of portal vessels and to sinusoidal endothelial cells. Conversely, in inflammatory liver diseases, ICAM-1 is markedly expressed on hepatocellular membranes [12, 13] in direct correlation to the degree of liver inflammation [5, 12, 14] . Seth [2] and Rothlein [6] detected soluble isoforms of ICAM-1 (sICAM-1) in human serum samples by immunoblotting and by ELISA technique, respectively [2, 6, 7, 9, 14] .
Some well-known sources of sICAM-1 are peripheral blood mononuclear cells [6, 8, 9] , endothelial cells, tumor cells, and many other cells, including hepatocytes [10, 12] . Both the tissue form and the soluble form are functionally active; in particular, they are able to bind LFA-1 and can be detected at low levels in sera from healthy individuals [2, 6, 8] . It may interfere with the adhesion between LFA-1 on activated lymphocytes and ICAM-1 on endothelium, thus preventing attachment or promoting detachment and eventually blocking transendothelial cell migration. Finally, it may be released from damaged or inflamed tissues [6, 8, 15] . The studies published so far report an increase of sICAM-1 concentrations in a variety of chronic liver diseases and/or in hepatocellular carcinoma (HCC); sICAM-1 may be shed from inflammatory cells, may be secreted by he-patocytes stimulated by inflammatory mediators, or may derive from passive liberation by necrotic hepatocytes [14] [15] [16] .
A positive correlation between sICAM-1 levels and serum alanine transaminase (ALT), g glutamyl transpeptidase (GGT), prothrombin activity, serum levels of gamma globulins, histological disease activity, and response to antiviral treatment has been found [13, 14, 17] . A decreased level of sICAM-1 seems to be correlated with successful treatment, and some authors have investigated whether it may be a useful marker to monitor disease activity and the effects of therapy, but the results are not conclusive [2, 7, 11, 13, 18, 19] .
Many different prognostic markers for the response to IFN treatment have been identified, with different relevance and meaning (GGT, iron, age, sex, length of the illness, and viremia). Moreover, it is well recognized that patients with viral genotype 1 have a worse response than patients with viral genotype 2 or 3 [20, 21] . The aim of our study was to verify whether sICAM-1 serum level variation may be considered an early prognostic marker for the response to antiviral treatment in chronic C hepatitis and whether the serum level of this molecule is positively correlated to the severity of liver disease.
Patients and Methods
Patients. Seventy-one consecutive patients affected by hepatitis C virus (HCV)-related chronic liver disease were enrolled in this study from January 1996 through December 1997. The inclusion criteria for IFN treatment were an increase in ALT level for at least 6 months, HCV infection, and a liver biopsy done in the previous year that confirmed the diagnosis of HCV-related chronic active hepatitis (CAH) or active cirrhosis.
Conversely, we excluded all patients positive for hepatitis B surface antigen (HbsAg) and/or hepatitis B core antigen (HbcAb) IgM or positive for nonorgan-specific autoantibodies at a level 11 : 80. Patients with decompensated cirrhosis and/or HCC, evidence of other malignancies, hyper-or hypothyroidism, presence of antithyroid antibodies, severe kidney failure, or cardiopathy were also not admitted to the trial. We also excluded patients with marked psychodepression, drug addiction, alcoholism, or previous treatment with corticosteroids during the previous 3 months; patients who were anti-human immunodeficiency virus (HIV) serum positive; patients who were pregnant; and patients aged 170 years. The patients were compared with a control group of 42 healthy sexand age-matched volunteer blood donors with normal findings from liver tests and with normal levels for erythrocyte sedimentation rate and acute phase proteins.
There was a similar percentage of smokers (29.5% vs. 28.5%) in both groups. We did not notice any acute intercurrent disease, and none of the patients were affected by allergic disorders during therapy. Before admission to therapy, each patient was submitted to abdominal ultrasound tomography and routine laboratory tests (complete blood count and liver, kidney, and clotting function tests).
Detection of HCV infection. The presence of HCV infection was diagnosed by use of a third-generation ELISA test (Ortho HCV 3.0 ELISA; Ortho Diagnostic System, Raritan, NJ) to detect anti-HCV antibodies, which was confirmed by Western blot (DECIS-CAN-HCV; Sanofi Pasteur, Paris), and by use the reverse transcription-nested polymerase chain reaction (PCR) to detect HCV-RNA [22, 23] . These tests were done before treatment and at the end of the trial. The identification of HCV genotypes was done by use of Inno-Lipa HCV II (Innogenetics, Ghent, Belgium) according to Simmonds's classification [24] Liver biopsy. The patients underwent a percutaneous liver biopsy during the year before the trial, to ascertain the diagnosis and to stage and grade the disease. Specimens of liver tissue, obtained by means of Hystocut needle, were fixed in formalin, embedded in paraffin, and stained with the following methods: hematoxylineosin, diastase-PAS, Perls's stain for iron, Gomori's method for reticulin, and orcein stain for elastic fibers [25] .
Standard criteria were used for histological diagnosis [26] . Semiquantitative assessment of histological features, such as lobular activity, fibrosis, and, in particular, portal-periportal activity, was carried out. In regards to portal-periportal activity, lobular activity, and hepatic fibrosis, a score from 0 to 4 was adopted according to the severity and the extent of the process [27] .
Detection of fibrogenesis markers. The fibrogenesis process was studied not only by means of liver histology but also by the evaluation of 2 serum markers: the aminoterminal peptide of type III procollagen (NPIIIP) and the pepsin-resistant fragment of laminin (laminin P1) [28] . NPIIIP, a marker of active fibrogenesis related to collagen deposition in portal tracts, was measured by use of the RIA-gnost PIIIP kit (CIS Bio-International, Gif-sur-Yvette, France). Laminin P1, a glycoprotein deposited in the space of Disse during sinusoidal capillarization, was measured by use of the RIAgnost Laminin P1 kit (CIS Diagnostic K.K., Tokyo).
sICAM-1. The detection and measurement of sICAM-1 serum levels were carried out by use of the Cellfree ICAM-1 Test Kit, according to the manufacturer's instructions (T Cell Diagnostics, Cambridge, MA), which is an ELISA test for the quantitative determination of soluble ICAM-1 levels in human sera that is able to detect serum levels of sICAM-1 as low as 0.3 mg/L with a variability intra-assay of !3%, and a variability interassay of !5% [15] . The results are expressed in micrograms per liter.
Treatment schedule and follow-up. All patients were treated with recombinant IFN-a-2a (Roferon A, Roche; F. Hoffmann-La Roche Cia S.A., Basel, Switzerland): 6 megaunits (MU) intramuscularly 3 times per week over 6 months and then 3 MU 3 times per week for another 6 months. Liver and kidney function tests and complete blood count were carried out once a month; sICAM-1, NPIIIP, and laminin P1 levels were determined before treatment and at 3, 6, and 12 months of treatment. Serum samples from each patient were collected and stored at Ϫ80ЊC.
Patients were considered to be "end-of-treatment responders" if HCV-RNA was not detectable in serum and if serum ALT levels had reached normal values (i.e., values less than of mean ‫ע‬ 2 SD healthy subjects) at the end of treatment [29] . Nonresponder patients were no longer treated after 4 months of therapy.
Statistical analysis Mean and standard deviation were computed for each variable. The mean values of the 2 groups of patients were compared by use of Student's t test for unpaired data; baseline and values collected thereafter were compared within each group by use of Student's t test for paired data. Nonparametric histological data were compared by use of Mann-Whitney U test (un- paired data). Fisher's exact test and/or x 2 test and linear correlation and regression analysis for continuous variables and Spearman's rank correlation coefficient for nonparametric variables were used to compare the frequencies and to study the relationships between variables. Finally, the prognostic value of sICAM-1 was studied using actuarial curves, which were compared by use of Kaplan Meier analysis and the log-rank test.
was considered sta-P ! .05 tistically significant. 14%] ). In the first group there were 4 patients affected by cirrhosis, whereas in the second there were 7 (not significant). All the responders are now in a follow-up program that will evaluate the incidence of relapse. Only 1 patient dropped out during the second month of therapy because of an acute myocardial infarction; this patient has not been considered in the statistical analysis.
Results

We
The 2 groups of patients did not statistically differ in age, for the values of ALT, AST, NPIIIP, and laminin P1, or in terms of histological features; GGT value alone showed a significant difference. Moreover, in the responder group we found 24 patients with a different HCV viral genotype other genotype 1, whereas in the nonresponder group there were only 10 ( ). The difference between sICAM-1 values of respond-P ! .001 ers and nonresponders was not statistically significant at baseline (table 2) . By contrast, the difference in sICAM-1 level between these 2 groups was highly significant at 3 months 2.73 ‫ע‬ 0.67 P ! .005 tients analyzed. These differences are the result of a decreased level in the responder group. Indeed, when we compared nonresponders and responders, we did not find a significant decrease in sICAM-1 level in the first group, whereas in the second group baseline sICAM-1 values were markedly higher than at 3, 6, and 12 months; the most relevant decrease in the concentration of sICAM-1 takes place within the first 3 months of therapy (table 3) . We therefore subdivided our patients on the basis of an early significant decrease in sICAM-1 level and found that in the group not showing a decrease within 3 months, the percentage of responders was 17.4%, whereas in the group with an evident decrease, the percentage was as high as 61.5% (  ; table 4 ). P ! .01 These differences are no longer evident at 6 months or later. We obtained similar results evaluating a decrease of sICAM-1 level of at least 10% of the baseline value with percentages of response of 30% and 59.4%, respectively, (
) and also a P ! .05 decrease of at least 1 (‫ע‬SD) of the normal value (0.34 mg/L) with response of 31.3% and 60%, respectively ( ).
The relationship between the response to the therapy and the decrease of sICAM-1 level within the first 3 months of treatment is similar to that between the viral genotype and the response. Indeed the patients with viral genotype different from 1 show much better results (responders 70.6%) than the group with genotype 1 (responders 17.1%) (
). Here we have P ! .001 found a strong correlation between the decrease of sICAM-1 and the viral genotype different from 1 ( ). P ! .002 The relevance of the decrease in sICAM-1 concentration during the first period of treatment was confirmed when we analyzed its prognostic value (Kaplan-Meier analysis). In the group of patients not showing a decrease in sICAM-1 levels, the probability of response at the end of the treatment was 14.4%, whereas in the group with a decrease the same probability went up to 60.7% (figure 1). This difference is highly significant ( ). When we evaluated the actuarial curves, analyzing P ! .001 only those cases showing a decrease of at least 10% or 1 SD from normal level, the result was confirmed: the probability of response in the first group was 29.1% and 30%, respectively, whereas in the second it was 58.1% and 58.9%, respectively ( ) . P ! .01
To check the possible and similar prognostic value of other common laboratory tests we analyzed the trend of ALT and GGT. These 2 tests did not allow distinguishing 2 different groups of patients with a different response to therapy. On the contrary, the analysis of the prognostic meaning of the viral genotype has given a result very similar to that of the decrease of sICAM-1 level, showing that the probability of response to IFN treatment is greater in the patients with HCV genotype different from 1 ( ). P ! .001
Discussion
Our data confirm that patients with chronic HCV-related hepatitis show higher levels of sICAM-1 than do control subjects, as reported by others [2, 6, 18, 19] . These results were not influenced by smoking, because the percentage of smokers was the same in both groups [30] . There was no interference either from cases of allergies [31] or from any concurrent severe illness during the period of observation [2, 9] .
The increase in sICAM-1 level can be explained by HCV activity, which damages both hepatocytes and sinusoidal vessels [32] and, in particular, endothelial cells. Inflammation and cytolysis lead to an up-regulation in the expression of tissue ICAM-1, which is mediated by proinflammatory cytokines [2, 8, 14] , and to an increase of sICAM-1, derived from hepatocytes and vascular endothelium [2, 6, 11] .
Baseline values of sICAM-1 in patients with CAH and in those with cirrhosis were different. In the latter, sICAM-1 was significantly higher, which confirms observations already reported by others [10, 11] . The explanation of these findings may be that sICAM-1 values seem to be more influenced by the characteristic features of cirrhosis, such as endothelial damage, capillarization of sinusoids, and vascularization of the newly formed matrix [28, 32, 33] , than they are by the damage of a purely inflammatory process, which occurs in hepatitis. This is confirmed by the finding that baseline values for sICAM-1 are closely and positively correlated not only to the indices of hepatic cytolysis (ALT and AST) [11, 14, 15, 34] but also to the markers of fibrogenesis and capillarization of the sinusoidal vessels (NPIIIP and laminin P1) [10] . The greater the biochemical activity and fibrogenesis in chronic liver diseases, the higher the levels of circulating sICAM-1. Furthermore, if we correlate sICAM-1 to the histological scores, we see a positive significant correlation only with fibrosis, whereas there is no correlation with portal inflammation and lobular necrosis. This finding, which differs from those reported by others [11, 14] , may be related to the prevalence and importance of endothelial damage over inflammatory damage. Moreover, as far as cirrhotic patients are concerned, a reduced hepatic clearance of sICAM-1 due to the presence of porto-systemic shunts may help explain the high levels of circulating sICAM-1 [7] .
We then divided our patients into responders and nonresponders to the therapy with IFN-a. At the beginning of the study, before treatment, the 2 groups did not differ from each other, except for GGT values, which were significantly higher in nonresponders. In particular, the concentration of sICAM-1 was the same (table 2) [34] ; this confirms the observation made by Yang et al. [15] regarding the lack of prognostic values of baseline levels of sICAM-1 for the response to treatment with IFN and seems to be in contrast with Bagnasco et al. [18] , who describe a significant higher level of sICAM-1 in responders, compared with nonresponders.
When we analyzed sICAM-1 at 3, 6, and 12 months of treatment, we found significant differences in the levels of sICAM-1 between responders and nonresponders (table 3) : lower levels of sICAM-1 were consistently present in the responders during the study. Indeed, only in this group was the baseline value higher than at all the subsequent value determinations.
In addition, the most significant decrease in sICAM-1 level occurred within the first 3 months of treatment, after which the values reached a steady state. In nonresponders, by contrast, the initial values remained substantially unchanged over a period of time. A reduction of sICAM-1 values in responders has been observed by other authors who noticed a similar behavior, not only in the serum but also in the tissues [7, 11, 13] . The decrease in sICAM-1 during treatment with IFN is probably due to both the direct antiviral effect and the immunomodulating characteristics of the drug. The reduction of hepatocyte cytolysis and of endothelial damage, as well as the attenuation of the proinflammatory stimuli, which accompany the positive response to treatment in the liver disease, probably lead to a reduction of sICAM-1. Therefore, we do not regard the reduction of sICAM-1 levels as a simple epiphenomenon of the reduction in inflammation.
With regard to response to treatment, if we compare the groups with and without a decreased serum level of sICAM-1 at 3 months, we find that the percentages of response are significantly different (60.7% responders in the first group and 14.4% in the second). These data remain consistent even if a decrease of sICAM-1 of at least 10% of the baseline value, or of at least 1 (‫ע‬SD) of normal values, is taken as the cutoff level.
Another relevant result is the close correlation between the trend of sICAM-1 levels and the viral genotype 1 or other viral genotypes. Our results seem to confirm a very similar prognostic utility in both sets of data.
The existence of 2 different groups of patients, characterized by the decrease or lack of decrease of sICAM-1, was further confirmed by observation of the actuarial curves, which makes possible the calculation of the probability to respond to treatment. This probability is much higher in the group showing an early decrease in sICAM-1, compared with the group where a decrease is not seen. These results highlight the importance of the timing of sICAM-1 measurements during the first 3 months of treatment, similar to the determination of the viral genotype at the start of the therapy.
Moreover, we have looked for the presence of HCV-RNA only at baseline and at the end of treatment, because the aim of our study was to evaluate the prognostic value of sICAM-1 decrease; indeed, it is well known that the early disappearance of HCV-RNA is positively correlated with a successful therapy. Our data have demonstrated that the sICAM-1 decrease has a similar prognostic value. By using the same statistical analysis, we evaluated the behavior of some common laboratory variables, such as ALT and GGT; these variables, however, did not show 2 groups of patients with significantly different prognosis in terms of the response to antiviral therapy.
The level of sICAM-1 until now has been used as a marker for the severity and/or the extent of the inflammatory process in a wide range of pathologies [9] . In particular, a negative correlation with regard to HCC has always been associated with survival or with the length of the period of remission after chemoembolization [35] . In inflammatory and/or autoimmune diseases, the measurement of sICAM-1 is considered a reliable test to monitor the pathological progression and the response to treatment [7, 11] .
Most of the reports thus far analyze a single measurement of sICAM-1 in the different diseases; we believe that a single test is of limited value and gives a "static" view of the sICAM-1 level, which can be useful in the diagnosis. Our results show that a "longitudinal" measurement of this glycoprotein is useful for identifying which patients are more likely to respond to treatment with IFN in the first 3 months of therapy [9, 11] . In conclusion, we suggest that the trend of sICAM-1 within the first 3 months of therapy has a predictive value for the response to IFN-a treatment in patients with CAH and may save money by giving further information about the advisability of the continuation of therapy.
